Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-l-cysteine in tumor derived cell lines

Biochemical Pharmacology

Volumn 79, Issue 6, 2010, Pages 864-872

  Tcherniuk, Sergey ^a   van Lis, Robert ^a   Kozielski, Frank ^b   Skoufias, Dimitrios A ^a  

^a INSTITUT DE BIOLOGIE STRUCTURALE   (France)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

Drug; Eg5; Mitosis; Monastrol; Resistance; STLC

Indexed keywords

ALANINE; ANTINEOPLASTIC AGENT; ARGININE; ASPARTIC ACID; GLUTAMIC ACID; ISOLEUCINE; KINESIN; KINESIN EG5; LEUCINE; MONASTROL; S TRITYLCYSTEINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR CELL LINE; TUMOR RESISTANCE; WILD TYPE;

ANTINEOPLASTIC AGENTS; BINDING SITES; CYSTEINE; DRUG RESISTANCE; HUMANS; INHIBITORY CONCENTRATION 50; KINESIN; MODELS, MOLECULAR; MUTATION; PROTEIN BINDING; PYRIMIDINES; THIONES;

EID: 74149091292     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.11.001     Document Type: Article

References (46)

1. Blangy A., Lane H.A., d'Herin P., Harper M., Kress M., and Nigg E.A. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 83 (1995) 1159-1169
2. Kashina A.S., Baskin R.J., Cole D.G., Wedaman K.P., Saxton W.M., and Scholey J.M. A bipolar kinesin. Nature 379 (1996) 270-272
3. Sharp D.J., Rogers G.C., and Scholey J.M. Microtubule motors in mitosis. Nature 407 (2000) 41-47
4. Kapitein L.C., Peterman E.J., Kwok B.H., Kim J.H., Kapoor T.M., and Schmidt C.F. The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks. Nature 435 (2005) 114-118
5. Jordan M.A., and Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 4 (2004) 253-265
6. Bhalla K.N. Microtubule-targeted anticancer agents and apoptosis. Oncogene 22 (2003) 9075-9086
7. Bergnes G., Brejc K., and Belmont L. Mitotic kinesins: prospects for antimitotic drug discovery. Curr Top Med Chem 5 (2005) 127-145
8. Sakowicz R., Finer J.T., Beraud C., Crompton A., Lewis E., Fritsch A., et al. Antitumor activity of a kinesin-inhibitor. Cancer Res 64 (2004) 3276-3280
9. Schmidt M., and Bastians H. Mitotic drug-targets and the development of novel antimitotic anticancer drugs. Drug Resist Updat 10 (2007) 162-181
10. Mayer T.U., Kapoor T.M., Haggarty S.J., King R.W., Schreiber S.L., and Mitchison T.J. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286 (1999) 971-974
11. Sarli V., and Giannis A. Targeting the kinesin spindle protein: basic principles and clinical implications. Clin Cancer Res 14 (2008) 7583-7587
12. Huszar D., Theoclitou M.E., Skolnik J., and Herbst R. Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev (2009)
13. Zhang Y., and Xu W. Progress on kinesin spindle protein inhibitors as anticancer agents. Anticancer Agents Med Chem 8 (2008) 698-704
14. DeBonis S., Skoufias D.A., Lebeau L., Lopez R., Robin G., Margolis R.L., et al. In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities. Mol Cancer Ther 3 (2004) 1079-1090
15. Debonis S., Skoufias D.A., Indorato R.L., Liger F., Marquet B., Laggner C., et al. Structure-activity relationship of S-trityl-l-cysteine analogues as inhibitors of the human mitotic kinesin Eg5. J Med Chem 51 (2008) 1115-1125
16. Ogo N., Oishi S., Matsuno K., Sawada J., Fujii N., and Asai A. Synthesis and biological evaluation of l-cysteine derivatives as mitotic kinesin Eg5 inhibitors. Bioorg Med Chem Lett 17 (2007) 3921-3924
17. Skoufias D.A., DeBonis S., Saoudi Y., Lebeau L., Crevel I., Cross R., et al. S-trityl-l-cysteine is a reversible, tight-binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression. J Biol Chem 281 (2006) 17559-17569
18. Gascoigne K.E., and Taylor S.S. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14 (2008) 111-122
19. Shi J., Orth J.D., and Mitchison T. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res 68 (2008) 3269-3276
20. Kozielski F., Skoufias D.A., Indorato R.L., Saoudi Y., Jungblut P.R., Hustoft H.K., et al. Proteome analysis of apoptosis signaling by S-trityl-l-cysteine, a potent reversible inhibitor of human mitotic kinesin Eg5. Proteomics 8 (2008) 289-300
21. Tao W., South V.J., Zhang Y., Davide J.P., Farrell L., Kohl N.E., et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 8 (2005) 49-59
22. Marcus A.I., Peters U., Thomas S.L., Garrett S., Zelnak A., Kapoor T.M., et al. Mitotic kinesin-inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. J Biol Chem 280 (2005) 11569-11577
23. Orth J.D., Tang Y., Shi J., Loy C.T., Amendt C., Wilm C., et al. Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate. Mol Cancer Ther 7 (2008) 3480-3489
24. Dagenbach E.M., and Endow S.A. A new kinesin tree. J Cell Sci 117 (2004) 3-7
25. Garcia-Saez I., DeBonis S., Lopez R., Trucco F., Rousseau B., Thuery P., et al. Structure of human Eg5 in complex with a new monastrol-based inhibitor bound in the R configuration. J Biol Chem 282 (2007) 9740-9747
26. Yan Y., Sardana V., Xu B., Homnick C., Halczenko W., Buser C.A., et al. Inhibition of a mitotic motor protein: where, how, and conformational consequences. J Mol Biol 335 (2004) 547-554
27. Zhang B., Liu J.F., Xu Y., and Ng S.C. Crystal structure of HsEg5 in complex with clinical candidate CK0238273 provides insight into inhibitory mechanism, potency, and specificity. Biochem Biophys Res Commun 372 (2008) 565-570
28. Cox C.D., Breslin M.J., Mariano B.J., Coleman P.J., Buser C.A., Walsh E.S., et al. Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett 15 (2005) 2041-2045
29. Kaan H.Y., Ulaganathan V., Hackney D.D., and Kozielski F. An allosteric transition trapped in an intermediate state of a new kinesin-inhibitor complex. Biochem J (2009) Sep 30. [Epub ahead of print]
30. DeBonis S., Simorre J.P., Crevel I., Lebeau L., Skoufias D.A., Blangy A., et al. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5. Biochemistry 42 (2003) 338-349
31. Maliga Z., Kapoor T.M., and Mitchison T.J. Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5. Chem Biol 9 (2002) 989-996
32. Krzysiak T.C., Wendt T., Sproul L.R., Tittmann P., Gross H., Gilbert S.P., et al. A structural model for monastrol inhibition of dimeric kinesin Eg5. EMBO J 25 (2006) 2263-2273
33. Brier S., Lemaire D., Debonis S., Forest E., and Kozielski F. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5. Biochemistry 43 (2004) 13072-13082
34. Brier S., Lemaire D., DeBonis S., Forest E., and Kozielski F. Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents. J Mol Biol 360 (2006) 360-376
35. Blangy A., Arnaud L., and Nigg E.A. Phosphorylation by p34cdc2 protein kinase regulates binding of the kinesin-related motor HsEg5 to the dynactin subunit p150. J Biol Chem 272 (1997) 19418-19424
36. Castillo A., Morse III H.C., Godfrey V.L., Naeem R., and Justice M.J. Overexpression of Eg5 causes genomic instability and tumor formation in mice. Cancer Res 67 (2007) 10138-10147
37. Wittmann T., Wilm M., Karsenti E., and Vernos I. TPX2, A novel xenopus MAP involved in spindle pole organization. J Cell Biol 149 (2000) 1405-1418
38. Brier S., Lemaire D., DeBonis S., Kozielski F., and Forest E. Use of hydrogen/deuterium exchange mass spectrometry and mutagenesis as a tool to identify the binding region of inhibitors targeting the human mitotic kinesin Eg5. Rapid Commun Mass Spectrom 20 (2006) 456-462
39. Cole D.G., Saxton W.M., Sheehan K.B., and Scholey J.M. A "slow" homotetrameric kinesin-related motor protein purified from Drosophila embryos. J Biol Chem 269 (1994) 22913-22916
40. Gordon D.M., and Roof D.M. The kinesin-related protein Kip1p of Saccharomyces cerevisiae is bipolar. J Biol Chem 274 (1999) 28779-28786
41. Kaseda K., Crevel I., Hirose K., and Cross R.A. Single-headed mode of kinesin-5. EMBO Rep 9 (2008) 761-765
42. Kavallaris M., Annereau J.P., and Barret J.M. Potential mechanisms of resistance to microtubule inhibitors. Semin Oncol 35 (2008) S22-S27
43. Giannakakou P., Sackett D.L., Kang Y.K., Zhan Z., Buters J.T., Fojo T., et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272 (1997) 17118-17125
44. Kavallaris M., Tait A.S., Walsh B.J., He L., Horwitz S.B., Norris M.D., et al. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res 61 (2001) 5803-5809
45. Geney R., Ungureanu M., Li D., and Ojima I. Overcoming multidrug resistance in taxane chemotherapy. Clin Chem Lab Med 40 (2002) 918-925
46. Luo L., Parrish C.A., Nevins N., McNulty D.E., Chaudhari A.M., Carson J.D., et al. ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism. Nat Chem Biol 3 (2007) 722-726